
					Posted by Chloe McGuire on Apr 14th, 2019 // Comments off Intercept Pharmaceuticals (NASDAQ:ICPT) had its target price raised by equities research analysts at Wells Fargo & Co  from $99.00 to $104.00 in a research report issued on Friday, Stock Target Advisor reports. The firm presently has a “market perform” rating on the biopharmaceutical company’s stock. Wells Fargo & Co‘s target price would indicate a potential upside of 9.23% from the stock’s previous close.Several other equities analysts also recently commented on ICPT. Zacks Investment Research downgraded Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 18th. UBS Group upped their price objective on Intercept Pharmaceuticals to $139.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. Wedbush  reiterated a “buy” rating and issued a $251.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, March 27th. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, April 9th. Finally, JMP Securities boosted their target price on shares of Intercept Pharmaceuticals from $175.00 to $200.00 and gave the company an “in-line” rating in a report on Wednesday, February 20th. Two research analysts have rated the stock with a sell rating, five have assigned  a hold rating and seventeen have issued  a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $144.05.Intercept Pharmaceuticals stock opened at $95.21 on Friday. Intercept Pharmaceuticals has a 12 month low of $64.50 and a 12 month high of $133.74. The company has a current ratio of 4.22, a quick ratio of 4.22 and a debt-to-equity ratio of 19.41. The company has a market capitalization of $2.83 billion, a P/E ratio of -8.77 and a beta of 1.63.  In other news, Director Paolo Fundaro sold 2,171 shares of the company’s stock in a transaction on Friday, March 29th. The shares were sold at an average price of $107.45, for a total value of $233,273.95. Following the transaction, the director now owns 11,114 shares of the company’s stock, valued at $1,194,199.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David Shapiro sold 2,000 shares of the company’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $111.51, for a total transaction of $223,020.00. Following the completion of the transaction, the insider now directly owns 42,543 shares in the company, valued at approximately $4,743,969.93. The disclosure for this sale can be found here. Insiders have sold a total of 30,504 shares of company stock worth $3,779,947 in the last three months. Insiders own  4.90% of the company’s stock. Institutional investors have recently added to or reduced their stakes in the company. Strs Ohio increased its holdings in shares of  Intercept Pharmaceuticals by 30.0% in the fourth quarter. Strs Ohio now owns 1,300 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 300 shares during the period.  Sofinnova Investments Inc. bought a new position in shares of  Intercept Pharmaceuticals in the fourth quarter worth $5,491,000.  Vanguard Group Inc increased its holdings in shares of  Intercept Pharmaceuticals by 2.8% in the third quarter. Vanguard Group Inc now owns 1,952,931 shares of the biopharmaceutical company’s stock worth $246,772,000 after purchasing an additional 54,038 shares during the period.  Macquarie Group Ltd. increased its holdings in shares of  Intercept Pharmaceuticals by 158.8% in the third quarter. Macquarie Group Ltd. now owns 35,561 shares of the biopharmaceutical company’s stock worth $4,493,000 after purchasing an additional 21,819 shares during the period.  Finally, AQR Capital Management LLC bought a new position in shares of  Intercept Pharmaceuticals in the third quarter worth $2,764,000. 70.24% of the stock is currently owned by hedge funds and other institutional investors. Intercept Pharmaceuticals Company ProfileIntercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).Featured Story: Why is insider trading harmful?Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.FY2019 Earnings Estimate for Constellium NV (CSTM) Issued By Seaport Global SecuritiesAnalyzing Crispr Therapeutics (CRSP) & Aevi Genomic Medicine (GNMX)